Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 9/20 | 0.54 |
| ▸ | MAOB | P27338 | 3/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.48 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.48 |
| ▸ | RXRA | P19793 | 1/20 | 0.47 |
| ▸ | RXRB | P28702 | 1/20 | 0.47 |
| ▸ | RXRG | P48443 | 1/20 | 0.47 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.47 |
| ▸ | PPIF | P30405 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 2/20 | 0.46 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2707335 | 0.90 | MRGPRX4 (0.54) | MRGPRX4MAOBFFAR1FFAR4RXRA | |
| SCHEMBL12998981 | 0.82 | MRGPRX4 (0.58) | MRGPRX4FFAR1FFAR4RXRARXRB | |
| SCHEMBL202627 | 0.81 | MAOB (0.56) | MRGPRX4MAOBNR4A2 | |
| SCHEMBL14829543 | 0.79 | MRGPRX4 (0.49) | MRGPRX4MAOBFFAR1FFAR4RXRA | |
| SCHEMBL202507 | 0.76 | MRGPRX4 (0.53) | MRGPRX4MAOBFFAR4 | |
| SCHEMBL2704584 | 0.75 | MRGPRX4 (0.48) | MRGPRX4FFAR1FFAR4NR4A2 | |
| SCHEMBL13532102 | 0.74 | MRGPRX4 (0.58) | MRGPRX4NR4A2 | |
| SCHEMBL19285699 | 0.74 | KDM1A (0.50) | MRGPRX4 | |
| SCHEMBL28316118 | 0.74 | KDM1A (0.50) | MRGPRX4 | |
| SCHEMBL2705640 | 0.74 | MRGPRX4 (0.52) | MRGPRX4MAOBFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8865736-B2 | Antibacterial agents | Biota Scientific Pty Ltd (AU) | 2014-10-21 | — | — | US | disclosed |
| US-8865736-B2 | Antibacterial agents | Biota Scientific Pty Ltd (AU) | 2014-10-21 | — | — | US | disclosed |
| US-20130072520-A2 | ANTIBACTERIAL AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2013-03-21 | — | — | US | disclosed |
| US-20130072520-A2 | ANTIBACTERIAL AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2013-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072520-A2 | ANTIBACTERIAL AGENTS | ALK, ROS1, NOX1 | MRGPRX4 3870/4885MAOB 604/4885FFAR1 754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.